Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; ICOone single-dose disposable dry powder inhaler; and ICOone nasal single-dose dry powder inhaler now for nasal use. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius to develop dry powder inhalation product, as well as collaboration with Monash h University to. to develop an inhalable and preventive oxytocin treatment to provide effective protection against cotries. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.
Stock data | 2024 | Change |
---|---|---|
Price | $0.6794339861939014 | N/A |
Market Cap | $6.95M | N/A |
Shares Outstanding | 10.22M | N/A |
Employees | 31.00 | N/A |